Soligenix, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Soligenix, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 5,448% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 95% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 96% of its market value (net cash). Higher than 88% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / -35%In 3 years sales changed by -100% while total assets changed by -35%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-90.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 81% of Healthcare companies in United States.
Cash Cushion Ratio
+96%Cash, after subtracting all debt, equals 96% of its market value (net cash).
Higher than 88% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Soligenix, Inc. made a loss over the last year. Soligenix, Inc. owes $0.55 for every $1 it owns. Soligenix, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossSoligenix, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.57The share price is 2.57 times Soligenix, Inc.'s book value per share, higher than 50% of Healthcare companies in United States.
Market cap
$8 MThe total market value of all of Soligenix, Inc.'s shares at today's price (share price × number of shares), smaller than 89% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$3 MWhat Soligenix, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
$0.14Net worth divided by the number of shares. The share price of $0.36 is 2.6 times this, which is the P/B above.
Return on equity (ROE)
-241.7%Soligenix, Inc. lost 241.7% of its shareholders' money over the last year, lower than 87% of Healthcare companies in United States.
Owes vs Owns
0.55×Soligenix, Inc. owes $0.55 for every $1 it owns (moderate), higher than 60% of Healthcare companies in United States.
Dividend yield
NoneSoligenix, Inc. does not currently pay a dividend.
Profit growth
LossSoligenix, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashSoligenix, Inc. held $8 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Soligenix, Inc.: $8 M ÷ $3 M (31 Mar 2026) = 2.6.
What is Soligenix, Inc.'s return on equity?
Soligenix, Inc. lost 241.7% of its shareholders' money over the last year, lower than 87% of Healthcare companies in United States.
How much does Soligenix, Inc. owe compared with what it owns?
Soligenix, Inc. owes $0.55 for every $1 it owns (moderate), higher than 60% of Healthcare companies in United States.
Does Soligenix, Inc. pay a dividend?
No. Soligenix, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.